Cartesian Therapeutics, Inc. entered into securities purchase agreement for issuance of 149,330 shares of series A preferred stock at a price of $403.468 for an aggregate gross proceeds of $60.25 million on November 13, 2023. Each share of series A preferred stock is convertible into 1,000 shares of common stock. The transaction will include participation from lead investor Timothy A. Springer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.03 USD | +0.62% | +17.42% | +1.68% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.68% | 374M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RNAC Stock
- News Cartesian Therapeutics, Inc.
- Cartesian Therapeutics, Inc. announced that it expects to receive $60.249876 million in funding